Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 17/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5482743 | 0.99 | F2R (0.57) | F2RKDM4ENPC1MAPTRAB9A | |
| SCHEMBL1731141 | 0.92 | F2R (0.58) | F2RKDM4ENPC1MAPTRAB9A | |
| SCHEMBL1730455 | 0.92 | F2R (0.61) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1728977 | 0.91 | F2R (0.59) | F2RKDM4ENPC1MAPTRAB9A | |
| Bromide SCHEMBL1730552 | 0.91 | F2R (0.61) | F2RKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14449044 | 0.89 | F2R (0.71) | F2R | |
| Bromide SCHEMBL1730448 | 0.88 | F2R (0.71) | F2RKDM4ENPC1MAPTRAB9A | |
| SCHEMBL14449156 | 0.87 | F2R (0.71) | F2RKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL1729249 | 0.86 | F2R (0.63) | F2R | |
| Bromide SCHEMBL1728717 | 0.86 | F2R (0.71) | F2RKDM4ENPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |